ASCO Preview: Alecensa Bests Xalkori In Japan Head-To-Head
This article was originally published in PharmAsia News
Executive Summary
Chugai has unveiled new details of positive head-to-head Japanese clinical results for its breakthrough cancer therapy alectinib, which showed benefits over close rival crizotinib in lung cancer.
You may also be interested in...
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
The latest drug development news and highlights from our FDA Performance Tracker.
Bumpy Japan Zolgensma Review Holds Lessons For Applicants
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports